High-resolution MRI analysis of XXXX xenograft on the @entity1573 chorioallantoic membrane.

@entity5 @entity1573 @entity1 @entity0
UNASSIGNED: The @entity1573 chorioallantoic membrane (CAM) model has been successfully used to study angiogenesis, @entity5 progression and its pharmacological treatment, @entity5 pharmacokinetics, and properties of novel nanomaterials. MRI is an attractive technique for non-invasive and longitudinal monitoring of physiological processes and @entity5 growth. This study proposes an age-adapted cooling regime for immobilization of the @entity1573 embryo, enabling high-resolution MRI of the embryo and the @entity5 xenograft. 64 @entity1573 embryos were enrolled in this study. The novel immobilization and imaging protocol was optimized in 29 embryos. From d7 to d18 immobilization of the embryo up to 90   min was achieved by cooling at 4     C pre-imaging, with cooling times adapted to age. Its application to @entity5 growth monitoring was evaluated in 15 embryos after xenotransplantation of @entity1 MDA-MB-231 @entity0 cells on CAM. @entity5 volumes were monitored from d4 to d9 after grafting (d11 to d16 after incubation) applying a T2 -weighted multislice RARE sequence. At d9 after grafting, the @entity5 were collected and compared with the MRI-derived data by histology and weight measurements. Additional imaging methods comprising DWI, T2 mapping, and the bio-distribution of contrast agents were tested at d9 after grafting in 20 further embryos. With the adaptive cooling regime, motion artifacts could be completely avoided for up to 90   min scan time, enabling high-resolution in ovo imaging. Excellent anatomical details could be obtained in the embryo and @entity5 . @entity5 volumes could be quantified over time. The results prove the feasibility of high-resolution MRI for @entity5 and organ growth monitoring. The suggested method is promising for future applications such as testing tailored and/or targeted treatment strategies, longitudinal monitoring of @entity5 development, analysis of therapeutic efficacies of drugs, or assessment of @entity5 pharmacokinetics. The method provides an alternative to animal experimentation. Copyright    2015 John Wiley _ Sons, Ltd.
